Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) CEO John Leonard sold 9,000 shares of the business's stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $11.99, for a total value of $107,910.00. Following the completion of the transaction, the chief executive officer directly owned 1,138,064 shares of the company's stock, valued at approximately $13,645,387.36. This trade represents a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Intellia Therapeutics Price Performance
NASDAQ NTLA opened at $11.86 on Wednesday. Intellia Therapeutics, Inc. has a fifty-two week low of $7.95 and a fifty-two week high of $18.48. The business has a fifty day moving average of $12.20 and a 200-day moving average of $13.06.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, meeting analysts' consensus estimates of ($0.80). The business had revenue of $7.66 million for the quarter, compared to analyst estimates of $12.98 million. Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%. The business's revenue for the quarter was down 46.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.98) earnings per share. Sell-side analysts forecast that Intellia Therapeutics, Inc. will post -3.21 EPS for the current year.
Institutional Investors Weigh In On Intellia Therapeutics
Several hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new stake in shares of Intellia Therapeutics in the second quarter valued at $260,721,000. Arrowstreet Capital Limited Partnership purchased a new position in Intellia Therapeutics during the first quarter worth about $17,913,000. Bank of America Corp DE purchased a new position in Intellia Therapeutics during the second quarter worth about $16,518,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Intellia Therapeutics during the second quarter worth about $15,210,000. Finally, Sumitomo Mitsui Trust Group Inc. boosted its stake in Intellia Therapeutics by 24.4% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,605,623 shares of the company's stock worth $43,484,000 after buying an additional 708,094 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.
Analyst Ratings Changes
A number of research analysts have issued reports on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Intellia Therapeutics in a report on Thursday, October 15th. Evercore raised shares of Intellia Therapeutics from a "hold" rating to an "outperform" rating and set a $24.00 price target on the stock in a research note on Friday, August 7th. Wolfe Research downgraded shares of Intellia Therapeutics from a "peer perform" rating to an "underperform" rating and set a $9.00 price target for the company. in a report on Wednesday, July 15th. Citizens Jmp reissued a "market outperform" rating and issued a $30.00 price objective on shares of Intellia Therapeutics in a research report on Wednesday, September 9th. Finally, Wedbush upped their price objective on shares of Intellia Therapeutics from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, seven have assigned a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $20.57.
View Our Latest Stock Analysis on NTLA
About Intellia Therapeutics
(
Get Free Report)
Intellia Therapeutics, Inc is a biotechnology company focused on developing potentially curative treatments using CRISPR-based gene-editing technology. The company is working to create therapies that can modify disease-causing genes inside the body, with the goal of addressing the underlying causes of serious genetic diseases rather than treating only their symptoms.
Intellia's pipeline has included NTLA-2001, an investigational in vivo gene-editing therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational therapy intended to target hereditary angioedema.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
